# Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

> **NCT01068392** · PHASE2 · COMPLETED · sponsor: **Dong-A University Hospital** · enrollment: 42 (actual)

## Conditions studied

- B-cell Lymphomas

## Interventions

- **DRUG:** Oxaliplatin, Prednisolone

## Key facts

- **NCT ID:** NCT01068392
- **Lead sponsor:** Dong-A University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2013-09
- **Final completion:** 2014-09
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-11-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01068392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01068392, "Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01068392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*